JP2019522461A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522461A5
JP2019522461A5 JP2018558287A JP2018558287A JP2019522461A5 JP 2019522461 A5 JP2019522461 A5 JP 2019522461A5 JP 2018558287 A JP2018558287 A JP 2018558287A JP 2018558287 A JP2018558287 A JP 2018558287A JP 2019522461 A5 JP2019522461 A5 JP 2019522461A5
Authority
JP
Japan
Prior art keywords
seq
grna molecule
set forth
nucleotide sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558287A
Other languages
English (en)
Japanese (ja)
Other versions
JP7075597B2 (ja
JP2019522461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031351 external-priority patent/WO2017193029A2/en
Publication of JP2019522461A publication Critical patent/JP2019522461A/ja
Publication of JP2019522461A5 publication Critical patent/JP2019522461A5/ja
Application granted granted Critical
Publication of JP7075597B2 publication Critical patent/JP7075597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558287A 2016-05-05 2017-05-05 デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物 Active JP7075597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332297P 2016-05-05 2016-05-05
US62/332,297 2016-05-05
PCT/US2017/031351 WO2017193029A2 (en) 2016-05-05 2017-05-05 Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2019522461A JP2019522461A (ja) 2019-08-15
JP2019522461A5 true JP2019522461A5 (https=) 2020-06-25
JP7075597B2 JP7075597B2 (ja) 2022-05-26

Family

ID=60203369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018558287A Active JP7075597B2 (ja) 2016-05-05 2017-05-05 デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物

Country Status (5)

Country Link
US (1) US20190134221A1 (https=)
EP (1) EP3452498B1 (https=)
JP (1) JP7075597B2 (https=)
ES (1) ES2957660T3 (https=)
WO (1) WO2017193029A2 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3341727B1 (en) 2015-08-25 2022-08-10 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したCas9蛋白質
EA201891317A3 (ru) * 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019122302A1 (en) 2017-12-21 2019-06-27 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Nucleic acid sequence replacement by nhej
JP2021511803A (ja) * 2018-01-31 2021-05-13 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法
US12152242B2 (en) 2018-04-23 2024-11-26 The Curators Of The University Of Missouri CRISPR therapy
EP3814510A4 (en) 2018-05-04 2022-02-23 University of Massachusetts MICROHOMOLOGY-MEDIATED REPAIR OF MICRODUPLICATION GENE MUTATIONS
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020018918A1 (en) * 2018-07-19 2020-01-23 The Board Of Trustees Of The University Of Illinois Methods for exon skipping and gene knockout using base editors
JP7460643B2 (ja) 2018-10-16 2024-04-02 ブルーアレル, エルエルシー 遺伝子へのdnaの標的化挿入のための方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート,インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3966327A1 (en) * 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
CN110499333A (zh) * 2019-08-01 2019-11-26 广州德赫生物科技有限公司 用于修复dmd基因突变的核酸序列及系统
CA3149259A1 (en) * 2019-10-02 2021-04-08 Christian Kupatt Treatment of diseases caused by frame shift mutations
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4069314A4 (en) * 2019-12-03 2024-06-26 Duke University SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
JP2023515710A (ja) * 2020-04-27 2023-04-13 デューク ユニバーシティ CRISPR媒介式エクソン欠失用の最適なgRNA対を発見するためのハイスループットスクリーニング法
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
WO2022060841A2 (en) 2020-09-15 2022-03-24 Research Institute At Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
WO2022087321A1 (en) * 2020-10-21 2022-04-28 Duke University Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
US20240366604A1 (en) 2021-04-28 2024-11-07 Graviton Bioscience Bv Selective inhibitors of rock2 for the treatment of muscular dystrophy
EP4399302A2 (en) * 2021-09-08 2024-07-17 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
WO2014197740A1 (en) * 2013-06-05 2014-12-11 The Trustees Of Columbia University In The City Of New York Mems-based calorimeter, fabrication, and use thereof
EP3004370B1 (en) * 2013-06-05 2024-08-21 Duke University Rna-guided gene editing and gene regulation
EP3748004A1 (en) * 2015-04-01 2020-12-09 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
EA201891317A3 (ru) * 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения

Similar Documents

Publication Publication Date Title
JP2019522461A5 (https=)
JP2018534950A5 (https=)
JP2019524149A5 (https=)
JP2017512767A5 (https=)
JP2016538885A5 (https=)
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
JP2020518276A5 (https=)
JP2016501532A5 (https=)
US10822617B2 (en) RNA-targeting fusion protein compositions and methods for use
JP2016521995A5 (https=)
JP2017006120A5 (https=)
JP2024153629A5 (https=)
JP2024038326A5 (https=)
JP2020022459A5 (https=)
JP2016537341A5 (https=)
JP2017079759A5 (https=)
JP2021502060A5 (https=)
JP2018143253A5 (https=)
JP2019519219A5 (https=)
JP2012528572A5 (https=)
CN114450031A (zh) 靶向rna的敲低和替代组合物及使用方法
FR2737500B1 (fr) Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
JP2018527013A5 (https=)
JP2018523668A5 (https=)
JP2019521139A5 (https=)